Regulatory Round-Up: Novartis, Sanofi and Arrowhead Secure CHMP Blessings

Why It Matters

CHMP endorsements accelerate European market entry, giving each company a competitive edge in high‑growth therapeutic niches and signaling regulatory confidence that can influence payer and investor sentiment.

Key Takeaways

• Sanofi's cenrifki gets CHMP positive opinion despite US liver concerns
• Arrowhead's redemplo may be first siRNA therapy for FCS, $1bn 2032 forecast
• Novartis' itvisma aims for EU approval, expanding SMA gene‑therapy options

Pulse Analysis

The CHMP’s recent positive opinions highlight a broader shift toward innovative, high‑value therapies in the EU. Sanofi’s cenrifki, a BTK inhibitor, leverages Phase III data showing a 31% reduction in six‑month disability progression for nrSPMS patients. While U.S. regulators flagged liver‑enzyme risks, the European panel’s endorsement suggests a more nuanced risk‑benefit assessment, potentially opening a sizable market for BTK inhibitors in multiple sclerosis, a space still dominated by Roche’s fenebrutinib.

Arrowhead’s redemplo (plozasiran) represents a rare‑disease breakthrough, targeting familial chylomicronemia syndrome with an 80% median triglyceride reduction and a marked decline in acute pancreatitis episodes. The drug’s siRNA platform could disrupt Ionis‑led dominance in the European FCS market, where Tryngolza and Waylivra currently lead. Analysts project redemplo to generate roughly $1 billion in revenue by 2032, underscoring the commercial upside of securing EMA approval and the strategic importance of first‑to‑market status in niche lipid disorders.

Novartis’ itvisma (onasemnogene abeparvovec) builds on the success of its U.S. launch, offering a one‑time SMN1 gene replacement that may reduce the need for chronic SMA treatments. The STEER trial demonstrated significant motor‑function gains over 52 weeks, positioning itvisma as a potential complement or alternative to Zolgensma, Evrysdi and Spinraza. An EU greenlight would not only expand Novartis’ SMA footprint but also reinforce the region’s growing appetite for gene‑therapy solutions, potentially accelerating payer adoption and setting new standards for rare‑disease care.